Crossmark

Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome

Crossref DOI link: https://doi.org/10.1186/s12885-018-5032-z

Published Online: 2018-11-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Grupp, Katharina http://orcid.org/0000-0003-2849-3743
Hofmann, Bianca

Kutup, Asad

Bachmann, Kai

Bogoevski, Dean

Melling, Nathaniel

Uzunoglu, Faik Guntac

El Gammal, Alexander Tarek

Koop, Christina

Simon, Ronald

Steurer, Stefan

Krech, Till

Burdak-Rothkamm, Susanne

Jacobsen, Frank

Sauter, Guido

Izbicki, Jakob

Wilczak, Waldemar
License Information

Text and Data Mining valid from 2018-11-12
More Information

Article History

Received: 7 March 2018

Accepted: 1 November 2018

First Online: 12 November 2018

Ethics approval and consent to participate

: The study was approved by the Ethics commission Hamburg (WF-049/09), Germany and conducted in accordance with the Declaration of Helsinki. Informed consent has not been collected specifically for the patient samples included in this study. Usage of routinely archived formalin fixed leftover patient tissue samples for research purposes by the attending physician is approved by local laws and does not require written consent (HmbKHG, §12,1).

: Not Applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.